Skip to main content
Fig. 1 | Retrovirology

Fig. 1

From: Therapeutic efficacy of albuvirtide-based antiretroviral therapy in people living with HIV who have low-level viremia and non-AIDS-defining malignancies: two case reports

Fig. 1

Serial chest CT imaging studies of Case 1 A: Contrast-enhanced chest CT (November 11, 2023) demonstrating a large left hilar mass (89 mm × 66 mm) with lobulation, spiculation, pleural indentation, and air bronchogram signs. Multiple nodular densities are present in both lungs with ground-glass opacities in the lower lobes. Enlarged bilateral hilar and mediastinal lymph nodes are visible (largest measuring 35 mm in long diameter). B: Follow-up chest CT (January 02, 2024) showing the evolution of the left hilar mass with associated changes in the surrounding lung parenchyma. C: Case 1 (Lung Cancer Patient). The graph demonstrates the temporal relationships between HIV diagnosis, initial antiretroviral therapy (TLE regimen), lung cancer diagnosis, cancer treatment initiation, ABT introduction, and subsequent modification to PD-1 inhibitor monotherapy. Note the rapid decline in viral load following ABT initiation despite severe immunosuppression related to cancer and its treatment. TLE: tenofovir disoproxil fumarate, lamivudine, and efavirenz; ABT: albuvirtide

Back to article page

Retrovirology

ISSN: 1742-4690

Contact us